Is intravenous B-12 administration safe, or only intramuscular
NICE technology appraisal TA875 (semaglutide 2.4 mg, Wegovy) recommends semaglutide as an option for managing overweight and obesity in adults when all of the following criteria are met: [2] [3] BMI of at least 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, obstructive sleep apnoea, or cardiovascular disease), or a BMI of 3034.9 kg/m in specific circumstances defined within the appraisal (for example, recent-onset type 2 diabetes) Treatment is delivered as part of a specialist multidisciplinary weight management service (Tier 3 or equivalent) Use is recommended for a maximum of two years under current NHS commissioning arrangements NICE technology appraisal TA1026 addresses tirzepatide (Mounjaro) for weight management, recommending it for adults with a BMI of 35 kg/m or above alongside at least one weight-related comorbidity, again within a specialist service context
[28] included fourteen trials enrolling 3,157,259 patients
Discuss the relapse with your prescriber to adjust your cessation plan, potentially adding varenicline or NRT if tirzepatide alone isnt sufficient
This side effect is generally transient but should be monitored if: You experience palpitations Theres a noticeable, sustained increase over time Its advisable to have regular cardiac assessments while on GLP-1 medication, especially if you have underlying heart conditions
ATF3 promotes ferroptosis in sorafenib-induced cardiotoxicity by suppressing Slc7a11 expression
